Now with FSSAI approval for Peak ATP in hand, TSI Group has granted exclusive licensing in the region to India’s GCV Life to further the ingredient’s business in India.
The Food Safety and Standards Authority of India (FSSAI) has granted registration approval to TSI Group’s (Missoula, MT) multi-patented Peak ATP 5’-triphosphate disodium ingredient. The company describes the ingredient as “a non-stimulant energy source that fuels muscles and powers the body’s movement.”
Now with FSSAI approval, TSI’s intention is to expand business for Peak ATP in India. To that end, TSI has granted exclusive licensing in the region to GCV Life (GCVL; Mumbai, India). GCVL will commercialize the ingredient in India.
According to both companies, Peak ATP can now capitalize on the plentiful opportunities in India’s sports nutrition market. In a press release, Shailesh Gadre, founder and director of GCVL, stated that the sports nutrition market has already grown more than 25% in India. GCVL and TSI expect the availability of Peak ATP in India to especially benefit smaller entrepreneurial firms.
“Previously, there was only a small penetration of sports nutrition products in India,” stated Gadre. “But since the pandemic, the middle class has begun to understand the importance of preventive healthcare and sports nutrition. The number of people who have become health conscious, physically active, and who are consuming products to support their active lifestyles has gone up considerably. We are already exploring new product concepts and discussing how we will educate consumers about Peak ATP’s benefits. The Indian consumer will now have a choice between [a] pure energy supplement (Peak ATP) and traditional energy and sugar drinks.”
TSI Group’s President Larry Kolb added in the press release, “Until now, most sports nutrition ingredients have been imported into India from the U.S., Europe, and Australia. Now, Indian sports nutrition companies will be moving forward. This also represents an incredibly exciting opportunity for our U.S. customers using Peak ATP to export their finished products to India.”
TSI says GCVL was instrumental in the registration process with FSSAI. (GCVL also represents TSI’s myHMB ingredient.) Before approving the ingredient, FSSAI inspected Peak ATP’s manufacturing, safety, and history of use, including evaluating preclinical safety studies, human clinical studies, and existing regulatory approvals in countries like the U.S. and Canada.